SK8402003A3 - Phenylethenyl or phenylethinyl derivatives as glutamate receptor or antagonists - Google Patents

Phenylethenyl or phenylethinyl derivatives as glutamate receptor or antagonists Download PDF

Info

Publication number
SK8402003A3
SK8402003A3 SK840-2003A SK8402003A SK8402003A3 SK 8402003 A3 SK8402003 A3 SK 8402003A3 SK 8402003 A SK8402003 A SK 8402003A SK 8402003 A3 SK8402003 A3 SK 8402003A3
Authority
SK
Slovakia
Prior art keywords
imidazole
methyl
alkyl
phenylethynyl
dimethyl
Prior art date
Application number
SK840-2003A
Other languages
English (en)
Slovak (sk)
Inventor
Vincent Mutel
Jens-Uwe Peters
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SK8402003A3 publication Critical patent/SK8402003A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91—Nitro radicals
    • C07D233/92—Nitro radicals attached in position 4 or 5
    • C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK840-2003A 2000-12-04 2001-11-26 Phenylethenyl or phenylethinyl derivatives as glutamate receptor or antagonists SK8402003A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00126615 2000-12-04
PCT/EP2001/013714 WO2002046166A1 (en) 2000-12-04 2001-11-26 Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
SK8402003A3 true SK8402003A3 (en) 2004-04-06

Family

ID=8170567

Family Applications (1)

Application Number Title Priority Date Filing Date
SK840-2003A SK8402003A3 (en) 2000-12-04 2001-11-26 Phenylethenyl or phenylethinyl derivatives as glutamate receptor or antagonists

Country Status (31)

Country Link
US (4) US6706707B2 (enExample)
EP (1) EP1349839B8 (enExample)
JP (2) JP4077317B2 (enExample)
KR (1) KR100515549B1 (enExample)
CN (1) CN1257894C (enExample)
AR (1) AR035401A1 (enExample)
AT (1) ATE288898T1 (enExample)
AU (2) AU2002229567B2 (enExample)
BG (1) BG107877A (enExample)
BR (1) BR0115871A (enExample)
CA (1) CA2430696C (enExample)
CZ (1) CZ20031795A3 (enExample)
DE (1) DE60108900T2 (enExample)
DK (1) DK1349839T3 (enExample)
EC (1) ECSP034640A (enExample)
ES (1) ES2248410T3 (enExample)
HR (1) HRP20030429A2 (enExample)
HU (1) HUP0400570A3 (enExample)
IL (2) IL155999A0 (enExample)
MA (1) MA26971A1 (enExample)
MX (1) MXPA03004862A (enExample)
NO (1) NO324326B1 (enExample)
NZ (1) NZ525917A (enExample)
PL (1) PL366222A1 (enExample)
PT (1) PT1349839E (enExample)
RS (1) RS43903A (enExample)
RU (1) RU2284323C9 (enExample)
SI (1) SI1349839T1 (enExample)
SK (1) SK8402003A3 (enExample)
WO (1) WO2002046166A1 (enExample)
ZA (1) ZA200303870B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
TW200424183A (en) * 2002-08-09 2004-11-16 Nps Pharma Inc New compounds
CN1894241A (zh) 2002-08-09 2007-01-10 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体－5调节剂的“1,2,4” 噁二唑
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
PT1603877E (pt) 2003-03-04 2009-02-11 Addex Pharma Sa Novos derivados de aminopiridina como antagonistas de mglur5
MXPA05009290A (es) 2003-03-07 2006-05-31 Astellas Pharma Inc Derivados heterociclicos que contienen nitrogeno que tienen estirilo 2,6-disustituido.
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
JP2006521358A (ja) * 2003-03-26 2006-09-21 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体のベンズアミドモジュレータ
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
AU2004247368B2 (en) 2003-06-12 2007-11-22 F. Hoffmann-La Roche Ag Heteroaryl-substituted imidazole derivatives as glutamate receptor antagonists
WO2005094822A1 (en) 2004-03-22 2005-10-13 Eli Lilly And Company Pyridyl derivatives and their use as mglu5 receptor antagonists
US7667041B2 (en) * 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
CA2568725C (en) * 2004-06-01 2012-11-27 F. Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
NZ551253A (en) 2004-06-01 2010-07-30 Hoffmann La Roche Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as MGLU5 receptor antagonists
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
DE102004044884A1 (de) * 2004-09-14 2006-05-24 Grünenthal GmbH Substituierte bizyklische Imidazo-3-yl-amin-Verbindungen
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
WO2006071730A1 (en) * 2004-12-27 2006-07-06 Astrazeneca Ab Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders
RU2401258C2 (ru) * 2005-03-16 2010-10-10 Авентис Фармасьютикалз Инк. Дипиразолы в качестве средств для центральной нервной системы
EP1863818B1 (en) * 2005-03-23 2010-03-10 F.Hoffmann-La Roche Ag Acetylenyl-pyrazolo-pvrimidine derivatives as mglur2 antagonists
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
US20090270623A1 (en) * 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
US20090048448A1 (en) * 2005-11-18 2009-02-19 Ikuo Kushida Salts of cynnamide compound or solvates thereof
KR20080069221A (ko) * 2005-11-24 2008-07-25 에자이 알앤드디 매니지먼트 가부시키가이샤 모르폴린 타입의 신나미드 화합물
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
AU2006328198B2 (en) * 2005-12-19 2013-07-18 Medizinische Hochschule Hannover Substituted phenol derivatives as analgesics
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
PL1992618T3 (pl) * 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
DE102006011574A1 (de) 2006-03-10 2007-10-31 Grünenthal GmbH Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln
US7737141B2 (en) * 2006-07-28 2010-06-15 Eisai R&D Management Co., Ltd. Prodrug of cinnamide compound
HRP20160950T1 (hr) 2006-12-21 2016-10-07 F. Hoffmann-La Roche Ag Polimorfi antagonista mglur5 receptora
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
CA2687262A1 (en) * 2007-05-16 2008-11-20 Naoyuki Shimomura One-pot production process for cinnamide derivative
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
TW200916469A (en) * 2007-08-31 2009-04-16 Eisai R & Amp D Man Co Ltd Multi-cyclic compounds
AU2009210070A1 (en) * 2008-01-28 2009-08-06 Eisai R & D Management Co., Ltd. Crystalline cinnamide compounds or salts thereof
US8323805B2 (en) 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
US8334287B2 (en) 2009-07-17 2012-12-18 Hoffmann-La Roche Inc. Imidazoles
US8642626B2 (en) 2010-07-29 2014-02-04 Taisho Pharmaceutical Co., Ltd. Ethinyl-pyrazole derivative
HUE040156T2 (hu) * 2010-11-05 2019-02-28 Oat Agrio Co Ltd Etinilfenilamidinvegyület vagy sója, eljárás azok elõállítására, és fungicid mezõgazdasági és kertészeti alkalmazásra
WO2012172093A1 (en) * 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
KR101291037B1 (ko) * 2011-10-12 2013-08-01 사회복지법인 삼성생명공익재단 레스베라트롤 유도체와 스티릴-오각형 방향족 화합물 및 이들의 베타-아밀로이드 플라그에 대한 결합제 및 진단영상제의 용도
EP3400220B1 (en) * 2016-01-05 2021-03-24 Hua Medicine (Shanghai) Ltd. Pyrazole derivatives
US10669255B2 (en) 2016-04-06 2020-06-02 Hua Medicine (Shanghai) Ltd. Pyrrole derivatives
MX2019008230A (es) 2017-01-10 2019-10-24 Bayer Ag Derivados heterociclicos como agentes de control de plagas.
KR20200035035A (ko) 2017-07-31 2020-04-01 노파르티스 아게 코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
EP4069685A1 (en) * 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303199A (en) 1963-07-15 1967-02-07 Geigy Chem Corp Certain imidazolone derivatives and process for making same
US3341548A (en) 1964-04-29 1967-09-12 Hoffmann La Roche Nitroimidazoles and their preparation
DE2035905A1 (de) * 1970-07-20 1972-02-03 Chemische Fabrik Stockhausen & Cie.,4150Krefeld Imidazolverbindungen und deren Herstellungsverfahren
CA1174673A (en) 1981-02-27 1984-09-18 Walter Hunkeler Imidazodiazepines
US4711962A (en) 1984-10-18 1987-12-08 Stauffer Chemical Company Process for selective preparation of ratios of isomers formed on N-substitution of asymmetric imidazoles
HU217958B (hu) 1989-06-30 2000-05-28 E. I. Du Pont De Nemours And Co. Helyettesített imidazolszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US5821937A (en) * 1996-02-23 1998-10-13 Netsuite Development, L.P. Computer method for updating a network design
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
CA2297732C (en) * 1997-08-14 2008-04-29 F. Hoffmann-La Roche Ag Heterocyclic vinylethers against neurological disorders
US6377987B1 (en) * 1999-04-30 2002-04-23 Cisco Technology, Inc. Mechanism for determining actual physical topology of network based on gathered configuration information representing true neighboring devices
CA2383524C (en) * 1999-08-31 2010-09-28 Merck & Co., Inc. Thiazolyl alkynyl compounds and methods of use thereof

Also Published As

Publication number Publication date
HUP0400570A3 (en) 2004-09-28
KR20040025878A (ko) 2004-03-26
BR0115871A (pt) 2003-10-28
BG107877A (bg) 2004-02-27
IL155999A0 (en) 2003-12-23
MA26971A1 (fr) 2004-12-20
PL366222A1 (en) 2005-01-24
RU2284323C9 (ru) 2007-01-20
US6706707B2 (en) 2004-03-16
NO20032503D0 (no) 2003-06-03
PT1349839E (pt) 2005-05-31
US20050131043A1 (en) 2005-06-16
AR035401A1 (es) 2004-05-26
US20030225070A1 (en) 2003-12-04
US20020128263A1 (en) 2002-09-12
ZA200303870B (en) 2004-08-19
AU2956702A (en) 2002-06-18
HUP0400570A2 (hu) 2004-06-28
KR100515549B1 (ko) 2005-09-20
SI1349839T1 (enExample) 2005-08-31
MXPA03004862A (es) 2005-02-14
CN1478080A (zh) 2004-02-25
DE60108900D1 (en) 2005-03-17
CA2430696C (en) 2009-01-27
RU2284323C2 (ru) 2006-09-27
US20030208082A1 (en) 2003-11-06
CN1257894C (zh) 2006-05-31
ES2248410T3 (es) 2006-03-16
EP1349839A1 (en) 2003-10-08
HRP20030429A2 (en) 2005-04-30
IL155999A (en) 2009-09-01
DE60108900T2 (de) 2006-01-12
EP1349839B8 (en) 2005-06-22
US6927232B2 (en) 2005-08-09
NO324326B1 (no) 2007-09-24
HK1063318A1 (en) 2004-12-24
RS43903A (sr) 2006-12-15
CA2430696A1 (en) 2002-06-13
US6972299B2 (en) 2005-12-06
EP1349839B1 (en) 2005-02-09
ECSP034640A (es) 2003-07-25
NO20032503L (no) 2003-06-03
NZ525917A (en) 2005-11-25
DK1349839T3 (da) 2005-06-06
CZ20031795A3 (cs) 2004-01-14
JP2008169206A (ja) 2008-07-24
WO2002046166A1 (en) 2002-06-13
JP4077317B2 (ja) 2008-04-16
AU2002229567B2 (en) 2007-09-06
ATE288898T1 (de) 2005-02-15
JP2004520292A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
SK8402003A3 (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor or antagonists
AU2002229567A1 (en) Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists
US5322950A (en) Imidazole with angiotensin II antagonist properties
US5817651A (en) 3-arylcarbonyl-1-(C-attached-N-heteryl)-1H-indoles
JP3593031B2 (ja) 神経学的障害に対する複素環式ビニルエーテル
AU684537B2 (en) Benzazepine derivative, pharmaceutical composition containing the same, and intermediate for the same
WO2007116092A1 (en) Enzyme inhibitors
AU2005272043A1 (en) Pyrazole amide derivatives, compositions containing such compounds and methods of use
US5389661A (en) Imidazole and 1,2,4-triazole derivatives with angiotensin II antagonist properties
US4859691A (en) Certain 1,2-benzisoxazole derivatives
NO323117B1 (no) Nye imidazolderivater
IE57446B1 (en) Substituted indoles
US5077299A (en) Imidazole substituted compounds which have useful pharmaceutical utility
MXPA06011243A (en) Therapeutic agents

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure